22Dec
Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced on December 17, 2020, that Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
On the heels of a new federal law requiring certain public federal buildings to provide lactation sp...
Read More >
In Fischer v. Sentry Ins. A Mutual Co., an employee kept a log of when she felt sexually harassed or...
Read More >
Recently, Illinois amended its Equal Pay Act to include a ban on salary-history inquiries, with the ...
Read More >
Eight Weeks and Counting to the Deadline. The California Consumer Privacy Act (CCPA) becomes effecti...
Read More >
The United States Army Corps of Engineers (Little Rock District) (“Corps”) issued a November 6th P...
Read More >
On August 30, 2019, Governor Newsom signed into law SB 778, which delays by one year the new harassm...
Read More >